CS-747S PhaseIII trial

CS-747S PhaseIII trial -Double-blinded comparative study for evaluation of efficacy and safety of CS-747S versus clopidogrel bisulfate in subject with acute coronary syndromes who are to undergo percutaneous coronary intervention-

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221302

Enrollment

1200

Registered

2010-11-10

Start date

2010-11-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subject with acute coronary syndromes who are to undergo percutaneous coronary intervention (PCI)

Interventions

investigational material(s) Generic name etc : CS-747S INN of investigational material : prasugrel Therapeutic category code : 339 Other agents relating to blood and body fluides Dosage and Administra

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Are 20 or above when informed consent is written. -Have recent acute coronary syndrome defined as a recent history of ischemic symptoms at rest associated with ECG changes consistent with ischemia and/or elevated cardiac enzymes, and are scheduled for PCI.

Exclusion criteria

Exclusion criteria: -High bleeding risk -Subjects who have severe complication to be treated (e.g. refractory arrhythmia, malignancy) -hepatic disease or renal disorder

Design outcomes

Primary

Measure	Time frame
Rate of MACE Calculating hazard ratio from event rate after administration of study drug.	—

Secondary

Measure	Time frame
The rate of bleeding event which is unrelated to CABG Evaluating the percentage of bleeding event.	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026